Additive effects of resveratrol and doxorubicin on bladder cancer cells

• Published in: Anti-cancer drugs
• Main Authors: Soares, Luciana Bicalho Moreira, Lima, Ana Paula Braga, Melo, André Sacramento, Almeida, Tamires Cunha, de Medeiros Teixeira, Luiz Fernando, da Silva, Glenda Nicioli
• Format: Journal Article
• Language: English
• Published: Wolters Kluwer Health, Inc. All rights reserved 27-08-2021
• ISSN: 0959-4973
• DOI: 10.1097/CAD.0000000000001218

The treatment of bladder cancer remains a challenge in clinical practice. Different chemotherapeutic protocols can be used; however, it is common to observe tumor recurrence and secondary effects that result in toxicity. Doxorubicin (DOX), one of the most effective anticancer agents used to treat bladder cancer, can cause chronic cardiotoxicity, limiting its use in clinical practice. Resveratrol (RES), a natural product with potential antitumor activity against bladder cancer, is associated with rapid metabolism and low bioavailability and needs to be combined with chemotherapeutic drugs to improve its use. Our study aimed to assess the therapeutic effect of a low concentration of DOX (2 µM) in combination with RES (150, 200 and 250 µM) on two bladder cancer cell lines. We investigated the mechanism of interaction between the drugs by performing cytotoxicity, clonogenic, oxidative stress, cell migration, cell morphology and nuclear division index (NDI) assays. Cytotoxicity evaluation revealed an additive interaction between RES and DOX for both cell lines. Additionally, the results of cell colony formation, oxidative stress, cell migration, cell morphology and NDI assays showed that a combination of DOX and RES was more effective than RES or DOX alone. In conclusion, a low concentration of DOX combined with RES could potentiate the antitumor effects of the drugs on bladder cancer cells, thus overcoming the secondary effects caused by DOX and the low bioavailability of resveratrol.